Education
About Us
Working with TipRanks
Follow Us
Neuropace, Inc. (NPCE)
NASDAQ:NPCE
NPCE Stock Chart & Stats
$16.94
-$0.66(-5.31%)
At close: 4:00 PM EST
$16.94
-$0.66(-5.31%)
Day’s Range― - ―
52-Week Range$7.56 - $18.98
Previous CloseN/A
Volume21.31K
Average Volume (3M)235.94K
Market Cap
$564.23M
Enterprise Value$352.78M
Total Cash (Recent Filing)$60.01M
Total Debt (Recent Filing)$71.18M
Price to Earnings (P/E)―
Beta0.49
Next Earnings
Mar 10, 2026EPS Estimate
-0.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.11
Shares Outstanding33,307,735
10 Day Avg. Volume366,301
30 Day Avg. Volume235,942
Financial Highlights & Ratios
PEG Ratio0.45
Price to Book (P/B)40.67
Price to Sales (P/S)4.08
P/FCF Ratio-17.85
Enterprise Value/Market Cap0.63
Enterprise Value/Revenue3.72
Enterprise Value/Gross Profit4.84
Enterprise Value/Ebitda-23.27
Forecast
1Y Price Target
$19.17Price Target Upside13.16% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.63
Revenue Forecast (FY)$98.44M
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy And SafetyNAUTILUS 18‑month and 12‑month results showing a large median reduction in generalized tonic‑clonic seizures and a favorable safety profile support clinical effectiveness and strong physician and patient endorsement.
Market OpportunitySubstantial unmet need among patients with medication‑resistant idiopathic generalized epilepsy and absence of approved neuromodulation or surgical options creates a meaningful addressable market for the RNS system.
Regulatory FilingFDA premarket approval supplement submission seeking label expansion for the RNS system to treat antiseizure‑medication resistant idiopathic generalized epilepsy could broaden the approved patient population.
Bears Say
Clinical Trial Outcome RiskFailure to achieve the primary effectiveness endpoint on time to a second generalized tonic‑clonic seizure increases regulatory uncertainty and may limit the scope of any approval.
Commercial And Distribution RiskNonrenewal of the distribution agreement with DIXI Medical may reduce market reach and put pressure on near‑term revenue until alternative commercial channels are established.
Reimbursement And Labeling UncertaintyMixed trial outcomes, with missed primary endpoint despite positive secondary results, could complicate pricing discussions and reimbursement decisions with payers.
NeuroPace News
NPCE FAQ
What was Neuropace, Inc.’s price range in the past 12 months?
Neuropace, Inc. lowest stock price was $7.56 and its highest was $18.98 in the past 12 months.
What is Neuropace, Inc.’s market cap?
Neuropace, Inc.’s market cap is $564.23M.
When is Neuropace, Inc.’s upcoming earnings report date?
Neuropace, Inc.’s upcoming earnings report date is Mar 10, 2026 which is in 49 days.
How were Neuropace, Inc.’s earnings last quarter?
Neuropace, Inc. released its earnings results on Nov 04, 2025. The company reported -$0.11 earnings per share for the quarter, beating the consensus estimate of -$0.195 by $0.085.
Is Neuropace, Inc. overvalued?
According to Wall Street analysts Neuropace, Inc.’s price is currently Undervalued.
Does Neuropace, Inc. pay dividends?
Neuropace, Inc. does not currently pay dividends.
What is Neuropace, Inc.’s EPS estimate?
Neuropace, Inc.’s EPS estimate is -0.17.
How many shares outstanding does Neuropace, Inc. have?
Neuropace, Inc. has 33,307,735 shares outstanding.
What happened to Neuropace, Inc.’s price movement after its last earnings report?
Neuropace, Inc. reported an EPS of -$0.11 in its last earnings report, beating expectations of -$0.195. Following the earnings report the stock price went up 38.085%.
Which hedge fund is a major shareholder of Neuropace, Inc.?
Currently, no hedge funds are holding shares in NPCE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
NeuroPace Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$19.17 (13.16% Upside)
$19.17 (13.16% Upside)
Blogger Sentiment
Bullish
NPCE Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 578.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.6%
Last 30 Days ▲ 76.8%
Last 30 Days ▲ 76.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
42.23%
12-Months-Change
Fundamentals
Return on Equity
-169.27%
Trailing 12-Months
Asset Growth
11.37%
Trailing 12-Months
Company Description
Neuropace, Inc.
NeuroPace, Inc. operates as a medical device company in the United States. It develops and sells RNS system, a brain-responsive neuromodulation system for treating medically refractory focal epilepsy by delivering personalized real-time treatment at the seizure source. The company's RNS system also records continuous brain activity data; and enables clinicians to monitor patients in person and remotely. It sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. The company was incorporated in 1997 and is headquartered in Mountain View, California.
NPCE Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong revenue growth, positive adjusted EBITDA, and increased guidance. There were challenges, including the winding down of the DIXI product line and extended timelines for pediatric indication, but these were outweighed by positive developments and strategic progress.View all NPCE earnings summariesNPCE Stock 12 Month Forecast
Average Price Target
$19.17
▲(13.16% Upside)
Technical Analysis
Delcath Systems
―
Senseonics Holdings
―
Tactile Systems Technology
―
RxSight
―
Ceribell, Inc.
―
Ownership Overview
Currently, No data available
---